Pregled bibliografske jedinice broj: 1272364
D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial
d-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial // World Journal of Urology, 32 (2013), 1; 79-84 doi:10.1007/s00345-013-1091-6 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1272364 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
D-mannose powder for prophylaxis of recurrent
urinary tract infections in women: a randomized
clinical trial
Autori
Kranjčec, Bojana ; Papeš, Dino ; Altarac, Silvio
Izvornik
World Journal of Urology (0724-4983) 32
(2013), 1;
79-84
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
D-mannose, UTI prevention
Sažetak
Purpose: To test whether D-mannose powder is effective for recurrent urinary tract infection (UTI) prevention. Materials and methods: After initial antibiotic treatment of acute cystitis, 308 women with history of recurrent UTI and no other significant comorbidities were randomly allocated to three groups. The first group (n = 103) received prophylaxis with 2 g of D-mannose powder in 200 ml of water daily for 6 months, the second (n = 103) received 50 mg Nitrofurantoin daily, and the third (n = 102) did not receive prophylaxis. Results: Overall 98 patients (31.8%) had recurrent UTI: 15 (14.6) in the D-mannose group, 21 (20.4) in Nitrofurantoin group, and 62 (60.8) in no prophylaxis group, with the rate significantly higher in no prophylaxis group compared to active groups (P < 0.001). Patients in D-mannose group and Nitrofurantoin group had a significantly lower risk of recurrent UTI episode during prophylactic therapy compared to patients in no prophylaxis group (RR 0.239 and 0.335, P < 0.0001). In active groups, 17.9% of patients reported side effects but they were mild and did not require stopping the prophylaxis. Patients in D-mannose group had a significantly lower risk of side effects compared to patients in Nitrofurantoin group (RR 0.276, P < 0.0001), but the clinical importance of this finding is low because Nitrofurantoin was well tolerated. Conclusions: In our study, D-mannose powder had significantly reduced the risk of recurrent UTI which was no different than in Nitrofurantoin group. More studies will be needed to validate the results of this study, but initial findings show that D-mannose may be useful for UTI prevention.
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE